Bilim insanlar\u0131, sa\u00e7 d\u00f6k\u00fclmesi tedavisinde mevcut ila\u00e7lardan daha etkili olabilece\u011fi belirtilen yeni bir y\u00f6ntem \u00fczerinde \u00e7al\u0131\u015f\u0131yor. \u00dc\u00e7 farkl\u0131 ilac\u0131n birlikte kullan\u0131ld\u0131\u011f\u0131 tedavi y\u00f6nteminin, sa\u00e7 b\u00fcy\u00fcmesini art\u0131rmada daha ba\u015far\u0131l\u0131 sonu\u00e7lar verdi\u011fi bildirildi
Sa\u00e7 d\u00f6k\u00fclmesine kar\u015f\u0131 \u00fc\u00e7l\u00fc ila\u00e7 formul\u00fc: Ba\u015far\u0131 oran\u0131 y\u00fczde 82 olan TH07 tedavisi.
Bilim insanlar\u0131, sa\u00e7 d\u00f6k\u00fclmesine kar\u015f\u0131 geli\u015ftirilen yeni bir tedavi y\u00f6ntemi \u00fczerinde \u00e7al\u0131\u015f\u0131yor. Ara\u015ft\u0131rmac\u0131lara g\u00f6re, tek bir ila\u00e7 yerine \u00fc\u00e7 farkl\u0131 ilac\u0131n birlikte kullan\u0131ld\u0131\u011f\u0131 bir kombinasyon tedavisi sa\u00e7 yeniden \u00e7\u0131k\u0131\u015f\u0131nda daha etkili olabilir.<\/p>\n\n\n\n
NYU Langone Health verilerine g\u00f6re erkeklerin y\u00fczde 80\u2019inden fazlas\u0131 ve kad\u0131nlar\u0131n neredeyse yar\u0131s\u0131 hayatlar\u0131n\u0131n bir d\u00f6neminde sa\u00e7 d\u00f6k\u00fclmesi ya\u015f\u0131yor.
Mevcut tedavilerin ba\u015far\u0131 oran\u0131 s\u0131n\u0131rl\u0131
New York Post’un haberine g\u00f6reg\u00fcn\u00fcm\u00fczde androgenetik alopesi (erkek tipi sa\u00e7 d\u00f6k\u00fclmesi) i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi (U.S. Food and Drug Administration) taraf\u0131ndan onaylanm\u0131\u015f yaln\u0131zca iki tedavi bulunuyor: Minoxidil ve Finasteride.
Uzmanlara g\u00f6re bu tedavilerin etkinli\u011fi s\u0131n\u0131rl\u0131 kalabiliyor. Ara\u015ft\u0131rmalarda finasteridin sa\u00e7 yeniden \u00e7\u0131k\u0131\u015f\u0131ndaki ba\u015far\u0131 oran\u0131n\u0131n y\u00fczde 31 ile y\u00fczde 66 aras\u0131nda de\u011fi\u015fti\u011fi, minoksidilin ise ortalama y\u00fczde 38 oran\u0131nda etkili oldu\u011fu belirtiliyor.
Ayr\u0131ca bu ila\u00e7lar\u0131n baz\u0131 yan etkiler ta\u015f\u0131yabildi\u011fi de ifade ediliyor.
Erkek tipi sa\u00e7 d\u00f6k\u00fclmesinde devrim: Yeni ila\u00e7 sa\u00e7 \u00e7\u0131k\u0131\u015f\u0131n\u0131 y\u00fczde 539 art\u0131rd\u0131
Erkek tipi sa\u00e7 d\u00f6k\u00fclmesinde devrim: Yeni ila\u00e7 sa\u00e7 \u00e7\u0131k\u0131\u015f\u0131n\u0131 y\u00fczde 539 art\u0131rd\u0131.
\u00dc\u00e7l\u00fc ila\u00e7 kombinasyonu geli\u015ftirildi.
Sa\u00e7 d\u00f6k\u00fclmesiyle m\u00fccadelede yeni bir yakla\u015f\u0131m geli\u015ftiren Triple Hair Inc., TH07 adl\u0131 bir topikal tedavi y\u00f6ntemi \u00fczerinde \u00e7al\u0131\u015f\u0131yor.
Bu y\u00f6ntem, \u00fc\u00e7 farkl\u0131 ilac\u0131n birle\u015fiminden olu\u015fuyor:
Finasteride
Minoxidil
Latanoprost
Latanoprost normalde glokom ve ok\u00fcler hipertansiyon tedavisinde kullan\u0131lan bir g\u00f6z damlas\u0131 olarak biliniyor.
Yap\u0131lan \u00e7al\u0131\u015fmalar, bu ilac\u0131n kirpik b\u00fcy\u00fcmesini te\u015fvik ederek kal\u0131nl\u0131k, uzunluk ve pigmentasyonu art\u0131rabildi\u011fini g\u00f6steriyor.
Minoksidil sa\u00e7 b\u00fcy\u00fcme d\u00f6ng\u00fcs\u00fcn\u00fcn b\u00fcy\u00fcme faz\u0131n\u0131 destekleyerek pasif sa\u00e7 k\u00f6klerini yeniden aktive ederken, finasterid ise sa\u00e7 k\u00f6klerinin k\u00fc\u00e7\u00fclmesine yol a\u00e7an DHT (dihidrotestosteron) hormonunu bask\u0131layarak sa\u00e7 kayb\u0131n\u0131 azaltmay\u0131 hedefliyor.
‘Kellik vir\u00fcs\u00fc’ Hindistan’\u0131 alarma ge\u00e7irdi: Bakanl\u0131k ani sa\u00e7 d\u00f6k\u00fclmelerini ara\u015ft\u0131r\u0131yor
‘Kellik vir\u00fcs\u00fc’ Hindistan’\u0131 alarma ge\u00e7irdi: Bakanl\u0131k ani sa\u00e7 d\u00f6k\u00fclmelerini ara\u015ft\u0131r\u0131yor
Klinik \u00e7al\u0131\u015fmada dikkat \u00e7eken sonu\u00e7lar
Yak\u0131n zamanda ger\u00e7ekle\u015ftirilen bir klinik \u00e7al\u0131\u015fmada, hafif ve orta d\u00fczeyde androgenetik alopesi ya\u015fayan erkekler d\u00f6rt farkl\u0131 gruba ayr\u0131ld\u0131.
Kat\u0131l\u0131mc\u0131lara 6 ay boyunca g\u00fcnde bir kez \u015fu tedaviler uyguland\u0131:
TH07 kombinasyon tedavisi
%0,1 finasterid
%0,03 latanoprost
%5 minoksidil
Ara\u015ft\u0131rma sonu\u00e7lar\u0131na g\u00f6re TH07 kullanan kat\u0131l\u0131mc\u0131lar\u0131n \u00e7o\u011fu, tek ila\u00e7 kullanan gruplara k\u0131yasla daha belirgin sa\u00e7 yeniden \u00e7\u0131k\u0131\u015f\u0131 bildirdi ve sa\u00e7lar\u0131n\u0131n g\u00f6r\u00fcn\u00fcm\u00fcnden daha memnun olduklar\u0131n\u0131 ifade etti.
TH07 grubunda:
Kat\u0131l\u0131mc\u0131lar\u0131n %52\u2019sinde yo\u011fun sa\u00e7 b\u00fcy\u00fcmesi,
%30\u2019unda ise orta d\u00fczeyde sa\u00e7 b\u00fcy\u00fcmesi g\u00f6zlendi.
Buna kar\u015f\u0131n finasterid, latanoprost veya minoksidil tek ba\u015f\u0131na kullan\u0131lan gruplarda \u00e7o\u011fu kat\u0131l\u0131mc\u0131da belirgin bir sa\u00e7 b\u00fcy\u00fcmesi g\u00f6r\u00fclmedi.
Ara\u015ft\u0131rmac\u0131lar sonu\u00e7lar\u0131 \u015fu ifadelerle de\u011ferlendirdi:
\u201cTH07\u2019nin topikal uygulanmas\u0131, androgenetik alopesinin tedavisinde her bir bile\u015fenin ayr\u0131 ayr\u0131 uygulanmas\u0131na k\u0131yasla daha y\u00fcksek etkinlik g\u00f6stermi\u015ftir.\u201d
Uzun ya\u015fam iste\u011fini yeni bir boyuta ta\u015f\u0131d\u0131: \u00d6l\u00fcm\u00fc yenmek isteyen milyarderden yeni y\u00f6ntem
Uzun ya\u015fam iste\u011fini yeni bir boyuta ta\u015f\u0131d\u0131: \u00d6l\u00fcm\u00fc yenmek isteyen milyarderden yeni y\u00f6ntem
Yan etki g\u00f6r\u00fclmedi.
Ara\u015ft\u0131rmada dikkat \u00e7eken bir di\u011fer bulgu ise TH07 kullanan kat\u0131l\u0131mc\u0131lar\u0131n herhangi bir cinsel ya da ciddi yan etki bildirmemesi oldu.
Ayr\u0131ca baz\u0131 ki\u015filerde ilac\u0131n b\u0131rak\u0131lmas\u0131ndan sonra da devam edebilen post-finasterid sendromu (PFS) ad\u0131 verilen bir durumun g\u00f6r\u00fclebildi\u011fi belirtiliyor.
Daha geni\u015f ara\u015ft\u0131rmalara ihtiya\u00e7 var
Ara\u015ft\u0131rmac\u0131lar, TH07 tedavisinin umut verici sonu\u00e7lar ortaya koydu\u011funu ancak \u00e7al\u0131\u015fman\u0131n baz\u0131 s\u0131n\u0131rlamalar\u0131 bulundu\u011funu vurgulad\u0131.
\u00c7al\u0131\u015fman\u0131n kat\u0131l\u0131mc\u0131 say\u0131s\u0131n\u0131n az olmas\u0131, yaln\u0131zca erkeklerden olu\u015fmas\u0131 ve tedavi s\u00fcresinin k\u0131sa olmas\u0131 nedeniyle daha kapsaml\u0131 klinik ara\u015ft\u0131rmalar yap\u0131lmas\u0131 gerekti\u011fi ifade edildi.
Bilim insanlar\u0131, uzun s\u00fcreli ve daha geni\u015f kat\u0131l\u0131ml\u0131 \u00e7al\u0131\u015fmalar\u0131n bu \u00fc\u00e7l\u00fc ila\u00e7 kombinasyonunun ger\u00e7ek etkinli\u011fini ortaya koyabilece\u011fini belirtiyor.<\/p>\n\n\n\n
haber kayna\u011f\u0131 https:\/\/gazeteoksijen.com\/saglik\/sac-dokulmesine-karsi-uclu-ilac-formulu-basari-orani-yuzde-82-olan-th07-tedavisi-269050<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Bilim insanlar\u0131, sa\u00e7 d\u00f6k\u00fclmesi tedavisinde mevcut ila\u00e7lardan daha etkili olabilece\u011fi belirtilen yeni bir y\u00f6ntem \u00fczerinde \u00e7al\u0131\u015f\u0131yor. \u00dc\u00e7 farkl\u0131 ilac\u0131n birlikte kullan\u0131ld\u0131\u011f\u0131 tedavi y\u00f6nteminin, sa\u00e7 b\u00fcy\u00fcmesini art\u0131rmada daha ba\u015far\u0131l\u0131 sonu\u00e7lar verdi\u011fi bildirildiSa\u00e7 d\u00f6k\u00fclmesine kar\u015f\u0131 \u00fc\u00e7l\u00fc ila\u00e7 formul\u00fc: Ba\u015far\u0131 oran\u0131 y\u00fczde 82 olan TH07 tedavisi.Bilim insanlar\u0131, sa\u00e7 d\u00f6k\u00fclmesine kar\u015f\u0131 geli\u015ftirilen yeni bir tedavi y\u00f6ntemi \u00fczerinde \u00e7al\u0131\u015f\u0131yor. Ara\u015ft\u0131rmac\u0131lara […]<\/p>\n","protected":false},"author":2,"featured_media":2831,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"jetpack_featured_media_url":"https:\/\/gundexia.com\/wp-content\/uploads\/2026\/03\/sac-dokulmesine-karsi-uclu-ilac-formulu-basari-orani-yuzde-82-olan-th07-tedavisi-ebcj.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/posts\/2807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/gundexia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2807"}],"version-history":[{"count":2,"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/posts\/2807\/revisions"}],"predecessor-version":[{"id":2826,"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/posts\/2807\/revisions\/2826"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gundexia.com\/index.php?rest_route=\/wp\/v2\/media\/2831"}],"wp:attachment":[{"href":"https:\/\/gundexia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gundexia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gundexia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}